ArticleCureus2025
Relationship Between Epicardial Adipose Tissue and Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Dabigatran outperforms warfarin in elderly patients with atrial fibrillation and stable coronary artery disease: reduced risks of bleeding and cardiovascular events.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
INTRODUCTION AND
aimHeart failure with preserved ejection fraction (HFpEF) is a significant clinical challenge, often coexisting with atrial fibrillation (AF), which exacerbates patient outcomes by increasing risks of stroke, hospitalizations, and mortality. Recent studies suggest that epicardial adipose tissue (EAT), a metabolically active fat depot, may contribute to AF pathogenesis by promoting atrial remodeling and fibrosis. This study aimed to evaluate the relationship between EAT thickness and AF in HFpEF patients. MATERIALS AND
methodsA total of 110 HFpEF patients were included, with 20 (18.2%) having documented AF. EAT thickness was measured using transthoracic echocardiography, and AF was confirmed via electrocardiography.
resultsPatients with AF had significantly greater EAT thickness compared to those without AF (8.3 ± 0.9 mm vs. 7.1 ± 0.8 mm, p < 0.001). Receiver operating characteristic (ROC) analysis demonstrated that EAT thickness was a strong predictor of AF (AUC = 0.87, p < 0.001), with a cut-off value of 7.5 mm achieving 89% sensitivity and 75% specificity.
conclusionThese findings indicate that increased EAT thickness is independently associated with AF in HFpEF patients, highlighting its potential as a biomarker for AF risk stratification. Future studies should explore whether targeting EAT could improve clinical outcomes in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.